Max Masucci
Stock Analyst at TD Cowen
(0.22)
# 4,119
Out of 4,827 analysts
23
Total ratings
16.67%
Success rate
-30.23%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $40.51 | +77.73% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $22.36 | +11.81% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $41.68 | +27.16% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $56.18 | +69.10% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $5.51 | +226.68% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $0.35 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.91 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $0.71 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $2.43 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $3.79 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.45 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.37 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.14 | +2,092.98% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $79.58 | +490.60% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $6.16 | +305.84% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $53.06 | +173.28% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $40.51
Upside: +77.73%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $22.36
Upside: +11.81%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $41.68
Upside: +27.16%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $56.18
Upside: +69.10%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $5.51
Upside: +226.68%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $0.35
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.91
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.71
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.43
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.79
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.45
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.37
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $1.14
Upside: +2,092.98%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $79.58
Upside: +490.60%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $6.16
Upside: +305.84%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $53.06
Upside: +173.28%